Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Though low serum magnesium (Mg) levels are associated with adverse outcomes in patients on haemodialysis, the interaction with calcimimetics remains uncertain. We hypothesized a potential joint interaction between serum Mg levels and calcimimetic use in cardiovascular events (CVEs), all-cause mortality, and any incident fractures in patients on haemodialysis.
This single-centre retrospective cohort included 399 Japanese adults on maintenance haemodialysis, followed for ≤5 years. Cox models with time-dependent serum Mg levels and calcimimetic usage interaction—adjusted for clinicodemographic and biochemical covariates. The model was adjusted for age, sex, dialysis vintage, diabetes, hypertension, coronary artery disease, corrected calcium, phosphate, intact parathyroid hormone, albumin, alkaline phosphatase, proton-pump inhibitor use, QTc interval of ECG, and abdominal aortic calcification -24 score.
At baseline, 205 patients (51.4%) were prescribed calcimimetics; the mean serum Mg level was 2.5 mg/dL. The mean observational period was 40.6 months, and 122 CVEs, 159 all-cause mortality, and 69 any incident fractures occurred (incidence rates: 0.09, 0.12, and 0.05 per patient-years), respectively. The time-dependent model showed serum Mg <2.4 mg /dL conferred a markedly higher risk for any incident fractures with calcimimetic non-use [hazard ratio (HR) 3.33, 95 % confidence interval (CI) 1.09–10.13]. The association persisted after the exclusion of patients with prior PTx (serum Mg levels, <2.4 mg/dL: HR 3.92, 95% CI 1.26–12.16). Serum Mg levels were not significantly associated with CVEs and all-cause mortality, regardless of calcimimetic usage. The restricted cubic spline curve demonstrated linear inverse trends of serum Mg levels with all-cause mortality and any incident fractures in calcimimetic non-use.
Time-dependent calcimimetic use and serum Mg levels showed that serum Mg <2.4 mg/dL were associated with a higher risk of any incident fractures in patients on haemodialysis without calcimimetic therapy, which appears to mitigate these risks. However, serum Mg levels had no measurable impact on CVEs and all-cause mortality regardless of calcimimetics use. These findings highlight Mg as a modifiable risk factor, particularly in calcimimetic-naïve patients. Prospective trials are warranted to determine whether Mg optimization can reduce fracture skeletal burden, particularly in calcimimetic non-users.
